drugset / Trial / NCT02748135
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
Timeline
- Start
- 2016-05
- Primary completion
- 2020-10-06
- Completion
- 2020-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TB-403 | Unknown | 20 mg/kg | Intravenous |
| Subject | TB-403 | Unknown | 50 mg/kg | Intravenous |
| Subject | TB-403 | Unknown | 100 mg/kg | Intravenous |
| Subject | TB-403 | Unknown | 175 mg/kg | Intravenous |